YMAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YMAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Y-mAbs Therapeutics's goodwill for the quarter that ended in Dec. 2023 was $0.00 Mil.
The historical data trend for Y-mAbs Therapeutics's Goodwill can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
Y-mAbs Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Y-mAbs Therapeutics (NAS:YMAB) Goodwill Explanation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Y-mAbs Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill-to-Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 127.869 | |
= | 0.00 |
Y-mAbs Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Goodwill-to-Asset (Q: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 127.869 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Gad | director, officer: President and Chairman | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Biotech Aps Wg | 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Johan Wedell-wedellsborg | director, 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Michael J Rossi | director, officer: President & CEO | 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Vignesh Rajah | officer: SVP and CMO | HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950 |
Bo Kruse | director, officer: EVP, CFO, Secy & Treas. | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Susan Laura Smith | officer: Senior Vice President, CCO | 5 OVERLOOK CT, LAMBERTVILLE NJ 08530 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Juan Moller San Pedro Claus | director, officer: Chief Executive Officer | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Mahiuddin Ahmed | officer: Sr. VP and CSO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Philip Karl Herman | officer: Sr. VP and CCO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Gregory S Raskin | director | C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
From GuruFocus
By GuruFocus Research • 11-13-2023
By Marketwired • 10-23-2023
By Marketwired • 09-06-2023
By PRNewswire PRNewswire • 03-17-2023
By GuruFocus Research • 12-03-2023
By sperokesalga sperokesalga • 05-26-2023
By PRNewswire PRNewswire • 03-20-2023
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 03-17-2023
By GuruFocus Research • 12-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.